Point-of-Care & Microfluidic Diagnostics Patent Landscape
Abbott Point of Care and Labrador Diagnostics together anchor a moderately concentrated field spanning 943 patent families, with the top five filers holding roughly a quarter of the hundred largest filers’ combined output. Annual filing volume peaked in 2018 and has since eased, placing the field in a maturing phase where differentiation is shifting toward enzyme/DNA assay integration and clinical informatics rather than core fluidic hardware.
Abbott and Labrador lead a moderately concentrated field
Abbott Point of Care Inc ranks first by patent records, closely trailed by Labrador Diagnostics LLC, which holds a nearly identical position. The two leaders collectively define the dominant technical paradigm—analyte measurement via integrated fluidic cartridges—and set the baseline any challenger must clear.
The top five filers account for 27% of the hundred largest filers’ combined total, indicating moderate concentration: no single player has a commanding lock, yet the gap between the top tier and the mid-tier (Novel Microdevices at rank three, followed by the Regents of the University of California and Janssen Pharma) is meaningful. Academic and institutional filers—MIT, the University of Texas system, Massachusetts General Hospital—populate the lower ranks, reflecting ongoing research-stage activity.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Abbott Point of Care Inc | 98 | |
| 2 | Labrador Diagnostics LLC | 97 | |
| 3 | Novel Microdevices LLC | 60 | |
| 4 | Regents of the University of California | 32 | |
| 5 | Janssen Pharmaceutica NV | 29 | |
| 6 | OPKO Diagnostics LLC | 27 | |
| 7 | Board of Regents, The University of Texas System | 25 | |
| 8 | DST DIAGNOSTISCHE SYST & TECHN | 24 | |
| 9 | BECTON DICKINSON & CO | 23 | |
| 10 | Massachusetts Institute of Technology | 22 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Theranos Inc | 19 | |
| 12 | THE STATE OF ISRAEL MINISTRY OF AGRICULTURE & RURA… | 17 | |
| 13 | Pharmanetics Inc | 16 | |
| 14 | IBM Corporation | 16 | |
| 15 | Cary James Miller | 15 | |
| 16 | The General Hospital Corporation (Massachusetts General Hospital) | 15 | |
| 17 | BioDigit Lab Corp | 15 | |
| 18 | Cranfield University | 14 | |
| 19 | Boehringer Ingelheim Vetmedica GmbH | 14 | |
| 20 | Rapid Pathogen Screening Inc | 13 |
The leaders’ positions imply that incremental cartridge and reader improvements will face heavy prior-art scrutiny; new entrants are more likely to find room in adjacent assay chemistries, informatics integration, or veterinary/agricultural diagnostics than in the core lateral-flow or electrochemical sensor space already densely covered by the top filers.
Patent publication typically lags filing by 18–24 months, so activity in 2024–2026 is under-represented in the current corpus and should not be read as a structural shift. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
A 2018 filing peak, now easing, across a hardware-dominant technology mix
The annual trend chart and the IPC composition chart together reveal both the temporal arc of the field and where technical attention has concentrated. Reading them in tandem helps identify which branches are saturated and which remain under-served.
Annual filing trend
Filings peaked in 2018 and have eased since, with the multi-year window still reflecting substantial accumulated activity. The apparent drop in 2024–2026 reflects publication lag rather than a real contraction; those cohorts are still materializing. Engineers should treat the 2017–2022 window as the most reliable signal of where competitive energy was concentrated.
↗ Hover for values · click a bar to ask EurekaTechnology composition
Material analysis and testing (G01N) and laboratory apparatus (B01L) dominate the composition, reflecting the core fluidic-cartridge and sensor hardware that defines the field. Enzyme and DNA assay methods (C12Q) rank third at a notably lower share, followed by bioreactor apparatus (C12M) and clinical diagnosis and surgery (A61B)—branches that represent technically adjacent but less-crowded territory. Semiconductor devices (H01L), MEMS (B81B), and nanotechnology (B82Y) each appear at small but non-trivial levels, signaling ongoing integration of microfabrication approaches.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Lab-on-a-chip for chemiluminescence-based microcha…
Disclosed herein is a microchannel lateral flow assay lab-on-a-chip device for point-of-care testing for detecting a target in a sample. The chip has a surface comprising a sample loading channel configured to receive the sample, a detection antibody conjugate channel configured to receive a first portion of the sample, a chemiluminescent substrate channel… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Apparatus and methods for analyte measurement and … | 566 |
| 2 | Apparatus and methods for analyte measurement and … | 423 |
| 3 | Molecular diagnostics system and methods | 275 |
| 4 | Point of care diagnostic systems | 264 |
| 5 | Devices and methods for detecting analytes using e… | 252 |
| 6 | Integration of fluids and reagents into self-conta… | 251 |
| 7 | Point-of-care analyzer module | 235 |
| 8 | Device for performing a diagnostic test and method… | 224 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the competitive structure means for R&D investment
Four structural observations—maturity, concentration, collaboration, and geography—frame the strategic choices available to existing players and new entrants in this field.
Post-peak field with maturing core hardware
Annual filing volume peaked in 2018 and has eased since, consistent with a field whose foundational fluidic and electrochemical sensor architectures are well-established in the prior art. R&D investment is more likely to yield defensible positions in adjacent chemistries or digital integration layers than in re-litigating core cartridge geometry. The easing trend does not signal exit—it signals that value capture is shifting toward application specificity and system integration.
Lifecycle: MaturingModerate concentration with a clear top-two tier
Abbott Point of Care and Labrador Diagnostics together set the technical baseline at the top of the ranking. The top five filers hold 27% of the hundred largest filers’ combined output, a level that is concentrated enough to create freedom-to-operate challenges in core areas but open enough that mid-tier players—Novel Microdevices, OPKO Diagnostics, Becton Dickinson—maintain distinct positions. Academic filers in the lower ranks indicate pre-commercial research pipelines that could surface as licensing targets or acquisition candidates.
Concentration: ModerateJanssen Pharma and Ortho Clinical Diagnostics show the field’s leading co-filing pair
The most active co-applicant relationship in the corpus is between Janssen Pharma NV and Ortho Clinical Diagnostics, who together filed 23 co-assigned patent records. Their shared technical focus on peptide/antibody reagents (C07K) and material analysis (G01N) suggests that diagnostics–pharma partnerships centering on immunoassay reagent development are the primary collaborative model. No other collaboration pair at this count level is present in the evidence.
Collaboration: Active pairUS-centric prosecution with meaningful PCT and EPO coverage
The United States is the dominant filing jurisdiction at the patent-record level, followed by Europe (EPO) and WIPO PCT filings. India ranks fourth, reflecting both local filing activity and international validation strategies. Japan, China, and South Korea each appear at lower levels, suggesting that Asian manufacturing jurisdictions are not yet prioritized for broad coverage by leading filers—an observation that may represent a prosecution gap or a deliberate focus on the US and European commercial markets.
Geography: US-ledGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Janssen Pharmaceutica NV | Ortho Clinical Diagnostics Inc | 23 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Abbott and Labrador anchor the field; Novel Microdevices is the most active recent entrant
The top of the ranking is notable for two near-equal leaders whose technical emphasis overlaps heavily in analyte measurement and fluidic lab apparatus, creating a dense prior-art environment in those subclasses. Below them, Novel Microdevices has emerged as the most active new entrant in recent cohorts.
Abbott Point of Care Inc
Abbott Point of Care holds the top position with 98 patent records, concentrated in material analysis and testing (G01N 33), laboratory apparatus (B01L 3), and electrochemical measurement (G01N 27). This breadth across both the assay chemistry and the physical cartridge/reader hardware reflects a vertically integrated portfolio strategy. Momentum data shows recent filings are consistent with a new-entrant pattern in the most recent cohort, suggesting portfolio activity may be shifting toward next-generation system architectures.
patent records: 98Novel Microdevices LLC
Novel Microdevices ranks third overall with 60 patent records, but stands out as a new entrant by momentum, with 27 patent records in the most recent filing cohort—the highest recent count among tracked applicants. Its focus is led by laboratory apparatus (B01L 3), analyte measurement (G01N 33), and automated testing (G01N 35), positioning it as a hardware-forward challenger targeting the cartridge and reader layer directly occupied by the top two filers.
patent records: 60| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Abbott Point of Care Inc | 1 | ▲ new entrant |
| Novel Microdevices LLC | 27 | ▲ new entrant |
| Labrador Diagnostics LLC | 3 | ▲ new entrant |
| Regents of the University of California | 2 | ▼ -85% |
Under-served branches adjacent to the dominant hardware core
Five IPC branches appear at lower relative shares despite plausible technical relevance to point-of-care diagnostics. Two stand out for the combination of tractable entry paths and meaningful technical value.
C12Q · Enzyme & DNA-based assay methods
Measuring and testing methods involving enzymes or nucleic acids (C12Q) account for a lower share of the composition relative to the hardware-dominant G01N and B01L branches, yet molecular diagnostics at the point of care—isothermal amplification, CRISPR-based detection—represents a rapidly growing clinical need. The branch is not empty, but the density gap versus core fluidic hardware suggests room for filers who integrate molecular assay chemistry directly into microfluidic cartridge architectures. Academic filers such as MIT and the Broad Institute already appear in the lower ranks, indicating early-stage prior art that could inform a freedom-to-operate strategy.
Search this in Eureka →A61B · Clinical diagnosis & patient-side measurement
The clinical diagnosis and surgery branch (A61B) has a notably smaller footprint than the laboratory apparatus and analyte measurement branches, even though patient-side physiological measurement is a core use case for point-of-care devices. This relative sparsity may reflect the tendency of leading filers to claim at the assay-chemistry or cartridge level rather than at the clinical-use level, creating a potential prosecution pathway for filers who frame innovations around specific clinical workflows—sepsis triage, cardiac biomarker monitoring, or decentralized chronic-disease management. Entry would benefit from co-development with clinical partners to anchor claim differentiation.
Search this in Eureka →How leading filers differ by technology route
Route coverage across the main technology branches in the current evidence set.
| Player | B01L 3 · Lab apparatus | G01N 33 · Material analysis & testing | C12Q 1 · Measuring & testing involving enzymes/DNA | G01N 27 · Material analysis & testing | G01N 35 · Material analysis & testing |
|---|---|---|---|---|---|
| Abbott Point of Care Inc | Strong · 61 | Strong · 65 | Absent | Moderate · 26 | Moderate · 16 |
| Theranos Inc | Strong · 43 | Strong · 68 | Emerging · 11 | Absent | Moderate · 29 |
| Novel Microdevices LLC | Strong · 48 | Strong · 37 | Emerging · 9 | Absent | Strong · 26 |
| Labrador Diagnostics LLC | Strong · 26 | Strong · 31 | Moderate · 9 | Absent | Strong · 17 |
| i-STAT Corporation | Strong · 21 | Absent | Absent | Strong · 20 | Strong · 15 |
| The State of Israel Ministry of Agriculture & Rural Development, Agricultural Research Organization, Volcani Center | Absent | Strong · 19 | Strong · 10 | Strong · 11 | Absent |
Frequently asked questions
The corpus covers 943 patent families. This figure represents the scope of the landscape analysis; applicant rankings and jurisdiction counts are reported at the patent-record level and can differ from the family total because a single family may generate multiple records across jurisdictions.
Abbott Point of Care Inc leads with 98 patent records, followed closely by Labrador Diagnostics LLC with 97. Novel Microdevices LLC ranks third with 60, and the Regents of the University of California and Janssen Pharma NV follow at 32 and 29 patent records respectively.
Annual filing volume peaked in 2018 and has eased since, placing the field in a maturing phase. The most recent cohorts (2024–2026) appear lower due to the 18–24 month publication lag and should not be interpreted as a structural decline. The multi-year accumulated corpus remains substantial at 943 patent families.
Material analysis and testing (G01N) and laboratory apparatus (B01L) together dominate the IPC composition, reflecting the core sensor and fluidic-cartridge hardware layer. Enzyme and DNA assay methods (C12Q), bioreactor apparatus (C12M), and clinical diagnosis (A61B) follow at lower but non-trivial levels.
The United States is the leading jurisdiction at the patent-record level, followed by Europe (EPO), WIPO PCT, and India. Japan, China, and South Korea each appear at lower levels, suggesting that Asian manufacturing jurisdictions receive less systematic coverage from the leading filers in this corpus.
The most active co-filing relationship identified in the evidence is between Janssen Pharma NV and Ortho Clinical Diagnostics, who together account for 23 co-assigned patent records. Their shared focus on peptide/antibody reagents (C07K) and analyte measurement (G01N) points to immunoassay reagent co-development as the primary collaborative model in this field.
Ready to map your own diagnostics patent landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.